chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Dose4 Pfizer /Dose 1,2,3 Moderna; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 06May2022 at 12:45 as dose 4 (booster), single (Lot number: FK9894) at the age of 69 years, in left arm for COVID-19 immunization. The patient's relevant medical history included: "known allergies: sulfa" (unspecified if ongoing); "known allergies: latex" (unspecified if ongoing). Concomitant medication(s) included: LOSARTAN; ATORVASTATIN. Past drug history included: Iodine, reaction(s): "known allergies: iodine"; Betadine, reaction(s): "known allergies: betadine". Vaccination history included: moderna (Dose Number: 3, Batch/Lot No. : OSIE 21A, Location of Injection: Arm Left), administration date: 28Oct2021, when the patient was 69-year-old, for COVID-19 Immunization, reaction(s): "Itching from my head to my torso", "rash on my wrists", "pinpoint numbness on lip"; moderna (Dose Number: 2, Batch/Lot No. : 023m20a, Location of Injection: Arm Left), administration date: 21Feb2022, for COVID-19 Immunization; moderna (Dose Number: 1, Batch/Lot No. : 032L20a, Location of Injection: Arm Left), administration date: 24Jan2021, when the patient was 68-year-old, for COVID-19 Immunization. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 06May2022, outcome "unknown", described as "Dose4 Pfizer /Dose 1,2,3 Moderna".  Additional information: Patient did not receive any other vaccines within 4 weeks. Other medical history was reported as healthy. Prior to vaccination the patient did not diagnosed with COVID-19. Since the vaccination the patient did not tested for COVID-19. Booster dose 5, Pfizer as bivalent (5H 9702) was admninistered on 28Sep2022 at 16:30 pm in left arm.
Palpable lymph node left armpit approx 46 hours after receiving TDAP vaccination in left deltoid.  Lymph node approx size of marble with swelling of surrounding tissue anteriorally to it.  Rates pain as 5 (1-10 scale) when palpated only.  Afebrile, full ROM Rue.  No erythema.
A nurse who was visiting this memory care inadvertently gave the second dose of Pfizer-BioNTech COVID-19 Vaccine 9 days after the first dose. The first dose was given on 2/2/2021. The second dose was given on 2/11/2021.  The memory care facility coordinator did not provide the patient's vaccine record card upon screening, nor the nurse or a pharmacy technician who was helping the vaccine clinic, checked the previous vaccine dose dates. The second dose was given on 2/11/2021 before noon. There was no signs or symptoms of abnormal reaction or behavior occurred to the patient. The patient seemed normal and stable; no medical attention was necessary.
Hives at 2nd dose, given ZYRTEC. Low grade fever on face, L & R legs, left & R arms, buttocks.
11/18/21-56-year-old male is coming in with nasal congestion cough and chills that started yesterday.  He reports he is vaccinated against COVID-19 since May. Review of Symptoms:   Review of Systems  Constitutional: Positive for chills. Negative for activity change, appetite change, fatigue and fever.  HENT: Positive for congestion, rhinorrhea and sore throat.   Respiratory: Positive for cough. Negative for shortness of breath, wheezing and stridor.   Cardiovascular: Negative for chest pain, palpitations and leg swelling.  Gastrointestinal: Negative for diarrhea, nausea and vomiting.  Skin: Negative for rash.  Neurological: Negative for dizziness and headaches.  All other systems reviewed and are negative. 11/19/21  Received Regeneron infusion
On 02/28/2005 (3rd) HepB vaccination administered by Police Academy Staff in upper left shoulder. The next day, arm was sore. On 03/02/2005 could not lift arm. On 03/03/2005 pain radiated from shoulder to elbow and upper forearm. 03/04/2005 symptoms worse. On 03/05/2005 no arm movement excruciating pain, went to ER. Treatment- Sling, X-rays, Bextra, and no work for 2 weeks
had a little rash; experienced much severe pain; This is a spontaneous report from a contactable consumer (patient). A 57-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: unknown, expiration date: unknown), via an unspecified route of administration on 18May2021 as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were unknown. Historical vaccine included, the patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: unknown, expiration date: unknown) via an unspecified route of administration, administered at an unspecified anatomical location on 05Apr2021 as dose 1, single for COVID-19 immunisation and experienced heart attack (13May2021) and shingles (16May2021). The patient had the second dose on 18May2021, the patient was not aware he had a shingles outbreak on 16May2021. Stated that he had internal shingles, which was different from what he previously had. On an unknown date, the patient only had a little rash, which was not that bad on the outside, but experienced much severe pain. The patient asked shingles may affect the second dose of the vaccine. The outcome of the events was unknown.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
Information has been received from a physician concerning a 44 year old female with intervertebral disc disorder. On 04/18/2001, the pt was vaccinated with hep b vaccine recombinant, polio, diphteria, tetanus and hep a. On 05/323/2001, the pt was vaccinated with the second dose hep b vaccine. On 07/13/2001, the p developed generalize sensory neuropathy described as
This case was reported by a other health professional via sales rep and described the occurrence of fever in a 81-year-old female patient who received SHINGRIX (batch number 273BZ, expiry date unknown) for prophylaxis. Previously administered products included ZOSTAVAX vaccine and SHINGRIX (1st dose received on 25th July 2018 (batch number 7X3EJ)). On 10th December 2018, the patient received the 2nd dose of SHINGRIX. On 10th December 2018, less than a day after receiving SHINGRIX, the patient experienced fever, chills and headache. On 12th December 2018, the patient experienced generalized macular rash and shingles. On an unknown date, the outcome of the fever, chills and headache were recovered/resolved and the outcome of the generalized macular rash and shingles were unknown. It was unknown if the reporter considered the fever, chills, headache, generalized macular rash and shingles to be related to SHINGRIX.   Additional details were reported as follows: Office manager mentioned to sales representative the day of treporting that one of her patients experienced side effects with Shingrix. The patient received 2 doses of Shingrix. After the 2nd dose and within 24 hours the patient experienced fever, chills and headache. It lasted about 24 hours. Two days after the second dose the patient noticed spots and a rash on her body.  The patient saw a dermatologist and was diagnosed with shingles.  Emergency room visit required. Initial reporter only had one address on file.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 30Sep2022 as dose 4 (booster), single (Lot number: GJ3277) at the age of 57 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Previous Stroke" (unspecified if ongoing); "Penicillin allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Patient had Paxlovid Treatment from 21Jun2023 to 24Jun2023.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300231399 same patient/drug, different dose/events;
18 hours post-injection: Fever of 102.2 F, mild headache, moderate muscle aches, chills 36 hours post: Mild fever, mild headache, roseola-like rash of chest (10 pin-point lesions per cm^2), diffuse erythema of upper and lower back
No additional AE; she administered a dose of PNEUMOVAX 23 that was expired.; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. Information of the patient's medical history, drug reaction/allergy, concurrent condition and concomitant therapy was not reported.  On 30-JAN-2023, the patient was administrated with a dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) 0.5 ml (lot #U026796, expiration date: 28-JAN-2023, strength, anatomical location and route of administration were not provided) for prophylaxis (expired product administered). The product had not undergone any temperature excursions. No additional adverse event (AE).
A few minutes after receiving my shot, I got really lightheaded and dizzy.  This feeling lasted about 5 minutes.  It scared me.
The problem is - a dull ache - it's there 24/7 since the day of the shot. I didn't worry about it the first several days. Then I called a Nurse Practitioner and then I called my doctor. I have to take an aspirin every night to get to sleep. I work through the day. It's low enough in pain level during the day that I can do my usual work. But I need to take aspirin at night for the pain so I can sleep.
Pt recvd 1st Engerix-B vax 1OCT91 & w/in 3 hrs of vax exp vertigo, muscle aches & back pain;
The patient experienced no symptoms; on 3/17/2020 an unspecified patient pulled away from the provider who was attempting to administer a dose of MMR II (lot S002503 ,expiration 7/23/2020)." The nurse reports that the patient did not receive the dose; Information has been received from a licensed practical nurse, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.      On 17-MAR-2020, the patient pulled away from the provider who was attempting to administer a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) (strength, dose detail and route were unknown; lot # S002503 and expiration date 23-JUL-2020) for prophylaxis. The patient did not receive the dose (circumstance or information capable of leading to medication error). The patient experienced no symptoms.
pt passed out after vaccine. checked blood pressure, gave water and food. pt waited in pharmacy area for almost an hour. still felt tight in chest like he was having an anxiety attack. did not want to go to the hospital and be exposed to other ill people. advised him that if he was still having issues to go to the hospital.
This spontaneous report as received from a registered nurse refers to a 61 year old female patient. On 21-APR-2016, the patient was vaccinated with a dose of ZOSTAVAX (lot # L029483 exp date 06-NOV-2016) (dose not reported) subcutaneously. Concomitant therapies included CARDIZEM. The nurse reported that in April 2016, the patient experienced a rash. The patient went to the office in August 2016 with rash over her whole body. The nurse stated that it was red skin bumps with follicular appearance of trunk, back, legs and arms. The patient was advised to take NSAIDS and BENADRYL. The patient also complained of heart arrhythmias. She was referred to the cardiologist. The nurse stated that the cardiologist stopped the patient's CARDIZEM. Subsequently, the patient called back towards the end of August 2016 and she was referred to an unspecified allergist and seen by an allergist in September 2016. The allergist stated that rash came on anytime in worsening heat. "Triamcinolone helped some". The allergist ordered allergy testing and took skin samples as well. The patient was negative for food allergies. Skin test was also negative. In January 2017, the patient was seen again with complaints of itching, no relief and rash all over the body; chest and limbs were the worst. The patient was also awake at night. The patient was given prednisone (manufacturer unknown), hydroxyzine and cetirizine hydrochloride. The patient was seen again in February 2017, the itching was still present and the medicine was helping. No other changes to medication were performed. At the time of the report, the patient had not recovered from rash and itching. The outcome for heart arrhythmias and awakening at night was unknown. Upon internal review heart arrhythmias were considered to be medically significant. Additional information has been requested.
Breakthrough COVID-19 case with unknown symptom status. Hospitalized 8/25/2021-8/29/2021. Death 8/29/2021. From Vital Records COD = RESPIRATORY FAILURE, COVID-19. Per vital records, COD ICD Codes include: Not yet coded ; Other Significant Conditions include: None listed. place of death: HOSPITAL-INPATIENT; certified, PRONOUNCING AND CERTIFYING PHYSICIAN.
pt recvd vax MAY95 & JUN95 & devel localized cellulitis p/each dose; her last mentrual period was 20SEP95;pt became pregnant;pregnancy was not established & @ 4wks exp a miscarriage;No further details were provided
This is a spontaneous case, initially received from a nurse on 18-Jan-2018, concerning a 45-month-old child female patient. The patient had no medical history. The patient did not receive any concomitant medications. On 12-Jan-2018, 03-year-old child (under 4 years of age) patient was administered with FLUVIRIN (dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 1721201 and expiry date: 30-Jun-2018) (explicitly coded as inappropriate age at vaccine administration). It was reported that, the patient did not experienced any adverse effects after the vaccination. The reporter assessed the event as non-serious. Follow up report received on 16-Feb-2018: The reporter confirmed that, the patient did not experienced any adverse effects after the vaccination.
03/13/2021, aches, chills, fever, weakness in legs, all COVID type symptoms, lasted 6 days.
Started to develop rash around the neck and bottom of neck top of chest area small area.  Raised almost like hives.  We contacted the doctors office.  The primary physician was not avaible but the partner was at the office.  I spoke with her.  The doctor stated give Benadryl.  The patient bought liquid Benadryl and took it.  The patients wife was going to drive home and if things progressed worse then she was going to take him to Hospital.  The doctor stated her main concern is respiratory problems.  The rash was not expanding.  Nothing else was swelling up.  He was not complaining of hard time breathing.  Everyone one was in agreement to the suggestion that the wife made. We have not heard anything.
The mother described a "knot as big as a goose egg" on the right leg on 3/21/01. Saw the doctor on 3/22/01. Redness that was 4x5cm, knot 3x4cm, mild cellulitis, right leg noted. Treated with Keflex. On 3/26/01 redness is resolved and knot reduced to 2x2cm.
She is enviably ill and she cannot keep even a sip of water down; she cannot even eat; Dry heaves; Diarrhea; She is enviably ill and she cannot keep even a sip of water down; she cannot even eat; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient received bnt162b2 (BNT162B2), administration date 07Apr2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: EATING DISORDER (non-serious), ILLNESS (non-serious) all with onset Apr2021, outcome "unknown" and all described as "She is enviably ill and she cannot keep even a sip of water down; she cannot even eat"; RETCHING (non-serious) with onset Apr2021, outcome "unknown", described as "Dry heaves"; DIARRHOEA (non-serious) with onset Apr2021, outcome "unknown", described as "Diarrhea".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Extreme joint pain. Wrists and knees could barely move without burning and aching. Could barely walk the next day, it felt like my joints were inflamed.
Father returned with patient to the office approximately 20 minutes after receiving vaccines. Father stated he was driving car and speaking with patient who was in seat behind him in her car seat. Father heard a gurgling sound and looked behind him. Patient was leaning forward with arms outstretched and fists clenched, unresponsive for approximately 30 seconds, then relaxed and complained of being sleepy and nauseous. At office exam was normal.
Redness & swelling (approximately 6 inches diameter) at injection site itchiness progressively worse since day of injection also bruising at site of injection (FLUVIRIN).
on 30APR93 mom reported pt to have a high pitched scream for 2 hrs in length approx 6 hrs p/1st set of immun was given on 26FEB93; mom states p/that episode pt was cranky for 2 days;
Client begin to feel numbness and tingling to right hand and fingers shortly after receiving vaccine. While being assessed by this nurse, client experienced syncope episode for approximately 10 seconds and was immediately alert and oriented to self, person, place and time after syncope episode.  Client became clammy and diaphoretic. 911 was called and client was assisted to triage area for further assessment. BP 164/96, HR 74. Client was cleared per EMT, able to walk out of clinic withou assistance and drive self home.
Extremely tight chest, racing/fluttering heart, sharp pain in left side of chest to breathe and especially take deep breaths. This occurred for 3 days with today being the day I went to the Emergency Room at 5 am due to the adverse event affecting my sleep.
Feel weird; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Feel weird) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (Feel weird). At the time of the report, FEELING ABNORMAL (Feel weird) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication and treatment was reported.
Patient got a pediatric pfizer (PEDS) vaccine at the 0.3mg dose. Patient will be instructed needs to come back for the correct 0.3mL dose with the adult pfizer vaccine. No adverse reaction noted.
Hair came out and still coming out. Face peel front of body back. By the hand food hair falling out.
Approximately 24 hrs after, I experienced a rash and hives on the inner arms, wrist, chest, and neck. I first noticed the neck rash. The rash is itchy occasionally.
lightheaded;dizzy, neck hurt, pvt MD notified;very dizzy upon standing, chest pain/tightness;sl red, puffy, firm, chest tightness, neck pain radiating up from lt arm;called MD to ER;
approx 12min p/vax pt c/o tightness in throat;no diff w/speech or breath;choked easily on sip of water;
Each injection increased her ability to function, increased heart rate variability, some of the effect wore off to some degree between vaccines, her overall condition has improved after vaccination.; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Each injection increased her ability to function, increased heart rate variability, some of the effect wore off to some degree between vaccines, her overall condition has improved after vaccination.) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020F21A and 050E21A) for COVID-19 vaccination.     Concurrent medical conditions included Disability (Chronic illness with long term disability.) and Illness (Chronic illness). Concomitant products included PREDNISONE and CLONAZEPAM (KLONOPIN) for an unknown indication.   On 31-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Each injection increased her ability to function, increased heart rate variability, some of the effect wore off to some degree between vaccines, her overall condition has improved after vaccination.). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Each injection increased her ability to function, increased heart rate variability, some of the effect wore off to some degree between vaccines, her overall condition has improved after vaccination.) outcome was unknown.            Other concomitant product use included medications for pain as needed.  Treatment information was not provided.
Persistent paresthesia from JE vaccine administration on 4-17-14 (#1); this was an aggravation of a pre-existing paresthesia (unk etiology).
Breakthrough case of COVID May 2022. Started with sx on 05/14/2022 -Sore throat, heavy mucus in the throat, nasal congestion, sinus headache. I took a home antigen test 05/16/2022  - positive. Sx today 05/17/2022 - nasal congestion and general weakness. Spoke to doctor this morning and prescribed a course of Paxlovid.
When I went to administer the vaccine into the deltoid the syringe was defective and most of the vaccine went out the side of the syringe and not into the patient's muscle. At least more than half of the dose was not administered.  After verifying the patient was okay I administered another dose as indicated.
The individual later took Moderna COVID-19 Vaccine as his second booster shot  and his reaction was much more severe as rash occurred on more than 50% of his body; This spontaneous case was reported by a consumer and describes the occurrence of RASH (The individual later took Moderna COVID-19 Vaccine as his second booster shot  and his reaction was much more severe as rash occurred on more than 50% of his body) in a 65-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 immunization.     No Medical History information was reported.    On an unknown date, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (The individual later took Moderna COVID-19 Vaccine as his second booster shot  and his reaction was much more severe as rash occurred on more than 50% of his body). The patient was treated with CORTISONE ACETATE (CORTISOL [CORTISONE ACETATE]) at an unspecified dose and frequency. At the time of the report, RASH (The individual later took Moderna COVID-19 Vaccine as his second booster shot  and his reaction was much more severe as rash occurred on more than 50% of his body) had resolved.            No concomitant medication was provided.  It was reported that the rash took 5-6 weeks to completely clear.  Treatment medication was not provided by the reporter.   This case was linked to MOD-2022-653582, MOD-2022-653585 (Patient Link).   Reporter did not allow further contact